Capricor Therapeutics (CAPR) Financials

$10.30 -1.56 (-13.15%)

Closing price 05/5/2025 04:00 PM Eastern

Extended Trading

$10.24 -0.06 (-0.53%)

As of 04:00 AM Eastern

Annual Income Statements for Capricor Therapeutics

This table shows Capricor Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-29	-22	-40
Consolidated Net Income / (Loss)	-29	-22	-40
Net Income / (Loss) Continuing Operations	-29	-22	-40
Total Pre-Tax Income	-29	-22	-40
Total Operating Income	-30	-24	-43
Total Gross Profit	2.55	25	22
Total Revenue	2.55	25	22
Operating Revenue	2.55	25	22
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	32	49	65
Selling, General & Admin Expense	10	13	15
Research & Development Expense	22	36	50
Other Special Charges / (Income)	0.03	0.01	0.11
Total Other Income / (Expense), net	0.71	1.79	2.10
Interest & Investment Income	0.52	1.73	2.20
Other Income / (Expense), net	0.19	0.07	0.01
Basic Earnings per Share	($1.18)	($0.83)	($1.15)
Weighted Average Basic Shares Outstanding	24.55M	26.78M	35.22M
Diluted Earnings per Share	($1.18)	($0.83)	($1.15)
Weighted Average Diluted Shares Outstanding	24.55M	26.78M	35.22M
Weighted Average Basic & Diluted Shares Outstanding	25.26M	31.40M	45.68M

This table shows Capricor Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-6.37	-7.72	-7.77	-7.37	-6.46	-0.70	-9.79	-11	-13	-7.06
Consolidated Net Income / (Loss)	-6.37	-7.72	-7.77	-7.37	-6.39	-0.76	-9.79	-11	-13	-7.12
Net Income / (Loss) Continuing Operations	-6.37	-7.69	-7.77	-7.37	-6.39	-0.77	-9.79	-11	-13	-7.00
Total Pre-Tax Income	-6.37	-7.69	-7.77	-7.37	-6.39	-0.77	-9.79	-11	-13	-7.00
Total Operating Income	-6.48	-8.07	-8.18	-7.75	-6.86	-1.28	-10	-12	-13	-7.70
Total Gross Profit	1.59	0.96	2.99	3.92	6.19	12	4.91	3.97	2.26	11
Total Revenue	1.59	0.96	2.99	3.92	6.19	12	4.91	3.97	2.26	11
Operating Revenue	1.59	-	2.99	3.92	6.19	12	4.91	3.97	2.26	11
Total Operating Expenses	8.07	9.06	11	12	13	13	15	16	15	19
Selling, General & Admin Expense	2.56	2.79	3.51	2.85	3.02	3.43	4.07	3.06	3.46	4.27
Research & Development Expense	5.50	6.23	7.66	8.82	10	9.94	11	13	12	15
Total Other Income / (Expense), net	0.11	0.38	0.42	0.38	0.47	0.52	0.47	0.59	0.45	0.58
Interest & Investment Income	0.11	0.38	0.42	0.38	0.48	0.45	0.47	0.59	0.45	0.69
Basic Earnings per Share	($0.26)	($0.31)	($0.31)	($0.29)	($0.25)	$0.02	($0.31)	($0.35)	($0.38)	($0.11)
Weighted Average Basic Shares Outstanding	24.43M	24.55M	25.25M	25.34M	25.82M	26.78M	31.35M	31.84M	33.09M	35.22M
Diluted Earnings per Share	($0.26)	($0.31)	($0.31)	($0.29)	($0.25)	$0.02	($0.31)	($0.35)	($0.38)	($0.11)
Weighted Average Diluted Shares Outstanding	24.43M	24.55M	25.25M	25.34M	25.82M	26.78M	31.35M	31.84M	33.09M	35.22M
Weighted Average Basic & Diluted Shares Outstanding	25.24M	25.26M	25.27M	25.78M	30.79M	31.40M	31.81M	32.54M	45.47M	45.68M

This table details how cash moves in and out of Capricor Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-25	5.09	-3.41
Net Cash From Operating Activities	4.92	-26	-40
Net Cash From Continuing Operating Activities	4.92	-26	-40
Net Income / (Loss) Continuing Operations	-29	-22	-40
Consolidated Net Income / (Loss)	-29	-22	-40
Depreciation Expense	0.53	1.07	1.43
Non-Cash Adjustments To Reconcile Net Income	4.50	-2.45	9.83
Changes in Operating Assets and Liabilities, net	29	-1.93	-11
Net Cash From Investing Activities	-35	5.11	-116
Net Cash From Continuing Investing Activities	-35	5.11	-116
Purchase of Property, Plant & Equipment	-2.00	-1.31	-1.17
Purchase of Investments	-114	-97	-208
Sale and/or Maturity of Investments	83	105	94
Other Investing Activities, net	-1.36	-0.74	-0.37
Net Cash From Financing Activities	4.87	26	153
Net Cash From Continuing Financing Activities	4.87	26	153
Issuance of Common Equity	4.80	26	152
Other Financing Activities, net	0.07	0.06	0.45
Cash Interest Paid	0.00	0.00	0.00
Cash Income Taxes Paid	0.00	0.00	0.00

This table details how cash moves in and out of Capricor Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-7.98	1.19	1.00	-0.77	-0.85	5.71	-8.48	4.47	58	-57
Net Cash From Operating Activities	-5.69	-6.90	4.21	-9.42	-8.79	-12	-1.27	-12	-12	-15
Net Cash From Continuing Operating Activities	-5.69	-6.90	4.21	-9.42	-8.79	-12	-1.27	-12	-12	-15
Net Income / (Loss) Continuing Operations	-6.37	-7.72	-7.77	-7.37	-6.39	-0.76	-9.79	-11	-13	-7.12
Consolidated Net Income / (Loss)	-6.37	-7.72	-7.77	-7.37	-6.39	-0.76	-9.79	-11	-13	-7.12
Depreciation Expense	0.14	0.19	0.23	0.25	0.28	0.31	0.33	0.36	0.36	0.38
Non-Cash Adjustments To Reconcile Net Income	1.11	1.18	2.19	1.61	1.72	-7.97	13	2.14	2.00	-7.57
Changes in Operating Assets and Liabilities, net	-0.56	-0.55	9.56	-3.92	-4.40	-3.17	-5.06	-3.79	-1.45	-0.49
Net Cash From Investing Activities	-4.18	5.14	-3.21	6.46	7.72	-5.86	-9.50	15	2.00	-123
Net Cash From Continuing Investing Activities	-4.18	5.14	-3.21	6.46	7.72	-5.86	-9.50	15	2.00	-123
Purchase of Property, Plant & Equipment	-0.56	-0.69	-0.35	-0.14	-0.27	-0.56	-0.61	-0.06	-0.01	-0.49
Purchase of Investments	-33	-32	-35	-18	-20	-25	-33	-16	-20	-139
Sale and/or Maturity of Investments	30	38	32	25	28	20	24	31	22	17
Other Investing Activities, net	-0.54	-0.53	-0.11	-0.10	-0.36	-0.17	-0.06	-0.02	-0.05	-0.25
Net Cash From Financing Activities	1.88	2.95	0.00	2.19	0.22	23	2.29	2.07	67	81
Net Cash From Continuing Financing Activities	1.88	2.95	0.00	2.19	0.22	23	2.29	2.07	67	81
Issuance of Common Equity	1.88	2.92	0.00	2.13	0.22	23	2.29	1.99	67	81
Other Financing Activities, net	0.00	0.03	0.00	0.06	-	0.00	0.00	0.08	0.12	0.25

This table presents Capricor Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	50	59	170
Total Current Assets	43	51	163
Cash & Equivalents	9.60	15	11
Short-Term Investments	32	25	140
Prepaid Expenses	0.92	1.00	1.50
Other Current Assets	0.55	10	10
Plant, Property, & Equipment, net	4.59	5.56	5.56
Total Noncurrent Assets	2.35	2.32	1.53
Other Noncurrent Operating Assets	2.35	2.32	1.53
Total Liabilities & Shareholders' Equity	50	59	170
Total Liabilities	38	36	25
Total Current Liabilities	24	31	21
Accounts Payable	4.83	6.25	8.19
Current Deferred Revenue	18	24	12
Other Current Liabilities	0.77	0.75	0.83
Total Noncurrent Liabilities	15	4.86	3.99
Other Noncurrent Operating Liabilities	1.88	4.86	3.99
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	12	23	145
Total Preferred & Common Equity	12	23	145
Preferred Stock	0.00	0.00	0.00
Total Common Equity	12	23	145
Common Stock	149	182	344
Retained Earnings	-137	-159	-200
Accumulated Other Comprehensive Income / (Loss)	0.11	0.24	1.03

This table presents Capricor Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	54	54	46	37	49	38	93
Total Current Assets	48	47	39	30	41	31	86
Cash & Equivalents	8.41	11	9.84	8.98	6.21	11	68
Short-Term Investments	38	35	28	20	34	19	17
Prepaid Expenses	0.34	0.88	0.58	0.46	1.13	0.84	0.39
Other Current Assets	0.55	0.55	0.55	0.55	0.37	0.37	0.41
Plant, Property, & Equipment, net	3.59	4.81	4.79	5.14	5.89	5.62	5.32
Total Noncurrent Assets	2.83	2.19	2.03	2.49	1.85	1.99	1.81
Other Noncurrent Operating Assets	2.83	2.19	2.03	2.49	1.85	1.99	1.81
Total Liabilities & Shareholders' Equity	54	54	46	37	49	38	93
Total Liabilities	39	48	43	39	31	27	25
Total Current Liabilities	23	37	35	33	26	22	20
Accounts Payable	3.94	5.41	5.13	6.77	6.25	6.17	6.53
Current Deferred Revenue	19	31	29	25	19	15	13
Other Current Liabilities	0.70	0.69	0.71	0.75	0.77	0.79	0.81
Total Noncurrent Liabilities	15	11	8.13	6.01	4.63	4.42	4.21
Long-Term Debt	3.38	3.38	3.38	3.38	3.38	3.38	3.38
Other Noncurrent Operating Liabilities	2.08	1.70	1.52	1.68	1.25	1.04	0.83
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	15	6.21	2.73	-1.79	18	12	68
Total Preferred & Common Equity	15	6.21	2.73	-1.79	18	12	68
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	15	6.21	2.73	-1.79	18	12	68
Common Stock	145	151	155	157	187	192	261
Retained Earnings	-129	-145	-152	-159	-169	-180	-193
Accumulated Other Comprehensive Income / (Loss)	0.12	0.09	0.18	0.11	0.31	0.15	0.10

This table displays calculated financial ratios and metrics derived from Capricor Therapeutics' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	941.85%	886.81%	-11.55%
EBITDA Growth	-46.14%	20.82%	-79.29%
EBIT Growth	-47.00%	18.63%	-77.25%
NOPAT Growth	-41.83%	18.92%	-76.78%
Net Income Growth	-44.93%	23.20%	-81.57%
EPS Growth	-35.63%	29.66%	-38.55%
Operating Cash Flow Growth	129.25%	-620.61%	-56.25%
Free Cash Flow Firm Growth	129.99%	-573.31%	-53.34%
Invested Capital Growth	-18,707.00%	36.34%	64.15%
Revenue Q/Q Growth	60.31%	79.20%	-4.12%
EBITDA Q/Q Growth	-5.01%	23.30%	-18.23%
EBIT Q/Q Growth	-5.34%	22.20%	-17.73%
NOPAT Q/Q Growth	-6.02%	21.98%	-17.75%
Net Income Q/Q Growth	-5.57%	23.79%	-18.63%
EPS Q/Q Growth	-4.42%	28.45%	-12.75%
Operating Cash Flow Q/Q Growth	-20.59%	-22.44%	-8.70%
Free Cash Flow Firm Q/Q Growth	36.53%	-17.85%	-4.58%
Invested Capital Q/Q Growth	4.62%	37.30%	54.78%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-1,135.57%	-91.12%	-184.69%
Operating Margin	-1,163.93%	-95.63%	-191.13%
EBIT Margin	-1,156.46%	-95.36%	-191.09%
Profit (Net Income) Margin	-1,137.37%	-88.52%	-181.71%
Tax Burden Percent	100.12%	100.00%	100.28%
Interest Burden Percent	98.23%	92.83%	94.82%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-134.49%	-129.63%	-48.16%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-64.55%	-44.12%	-37.13%
Return on Assets (ROA)	-63.48%	-40.96%	-35.31%
Return on Common Equity (ROCE)	-134.49%	-129.63%	-48.16%
Return on Equity Simple (ROE_SIMPLE)	-246.22%	-98.61%	-27.82%
Net Operating Profit after Tax (NOPAT)	-21	-17	-30
NOPAT Margin	-814.75%	-66.94%	-133.79%
Net Nonoperating Expense Percent (NNEP)	-23.58%	-13.97%	-11.17%
Return On Investment Capital (ROIC_SIMPLE)	-	-74.57%	-20.48%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	408.86%	50.87%	66.76%
R&D to Revenue	855.07%	144.76%	224.37%
Operating Expenses to Revenue	1,265.28%	195.65%	291.63%
Earnings before Interest and Taxes (EBIT)	-30	-24	-43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-29	-23	-41
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	8.27	6.66	4.31
Price to Tangible Book Value (P/TBV)	8.27	6.66	4.31
Price to Revenue (P/Rev)	38.19	5.98	28.18
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	23.28	4.41	21.37
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	12.08	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	10.61	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.29	0.00	0.00
Long-Term Debt to Equity	0.29	0.00	0.00
Financial Leverage	-1.62	-2.26	-1.14
Leverage Ratio	2.12	3.16	1.36
Compound Leverage Factor	2.08	2.94	1.29
Debt to Total Capital	22.27%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	22.27%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	77.73%	100.00%	100.00%
Debt to EBITDA	-0.12	0.00	0.00
Net Debt to EBITDA	1.31	0.00	0.00
Long-Term Debt to EBITDA	-0.12	0.00	0.00
Debt to NOPAT	-0.16	0.00	0.00
Net Debt to NOPAT	1.83	0.00	0.00
Long-Term Debt to NOPAT	-0.16	0.00	0.00
Altman Z-Score	-3.74	-1.82	13.72
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	1.82	1.63	7.77
Quick Ratio	1.76	1.26	7.21
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	5.60	-26	-41
Operating Cash Flow to CapEx	245.80%	-1,951.46%	-3,427.61%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.06	0.46	0.19
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.80	4.96	4.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-27	-17	-6.05
Invested Capital Turnover	-0.19	-1.16	-1.94
Increase / (Decrease) in Invested Capital	-26	9.64	11
Enterprise Value (EV)	59	111	476
Market Capitalization	97	151	627
Book Value per Share	$0.47	$0.73	$3.20
Tangible Book Value per Share	$0.47	$0.73	$3.20
Total Capital	15	23	145
Total Debt	3.38	0.00	0.00
Total Long-Term Debt	3.38	0.00	0.00
Net Debt	-38	-39	-152
Capital Expenditures (CapEx)	2.00	1.31	1.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-22	-20	-9.16
Debt-free Net Working Capital (DFNWC)	19	20	142
Net Working Capital (NWC)	19	20	142
Net Nonoperating Expense (NNE)	8.23	5.43	11
Net Nonoperating Obligations (NNO)	-38	-39	-152
Total Depreciation and Amortization (D&A)	0.53	1.07	1.43
Debt-free, Cash-free Net Working Capital to Revenue	-866.92%	-79.05%	-41.12%
Debt-free Net Working Capital to Revenue	756.51%	77.79%	639.23%
Net Working Capital to Revenue	756.51%	77.79%	639.23%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.18)	($0.83)	($1.15)
Adjusted Weighted Average Basic Shares Outstanding	24.55M	26.78M	35.22M
Adjusted Diluted Earnings per Share	($1.18)	($0.83)	($1.15)
Adjusted Weighted Average Diluted Shares Outstanding	24.55M	26.78M	35.22M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	25.26M	31.40M	45.68M
Normalized Net Operating Profit after Tax (NOPAT)	-21	-17	-30
Normalized NOPAT Margin	-813.81%	-66.92%	-133.43%
Pre Tax Income Margin	-1,136.02%	-88.52%	-181.20%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Capricor Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	288.66%	1,159.30%	64.29%	1.38%	-63.44%	-7.92%
EBITDA Growth	-63.31%	-24.98%	-2.79%	-6.74%	-3.90%	87.64%	-24.89%	-49.94%	-91.99%	-652.00%
EBIT Growth	-64.10%	-26.44%	-4.51%	-8.64%	-5.97%	84.12%	-25.43%	-49.62%	-89.52%	-500.79%
NOPAT Growth	-50.14%	-26.44%	-4.51%	-5.81%	-5.97%	84.12%	-25.43%	-49.62%	-89.52%	-500.79%
Net Income Growth	-62.04%	-24.72%	0.64%	-3.62%	-0.31%	90.13%	-26.08%	-49.32%	-96.49%	-833.83%
EPS Growth	-52.94%	-19.23%	3.13%	0.00%	3.85%	106.45%	0.00%	-20.69%	-52.00%	-650.00%
Operating Cash Flow Growth	-70.33%	-22.65%	-82.49%	-43.95%	-54.69%	-67.98%	-130.13%	-30.48%	-32.38%	-27.62%
Free Cash Flow Firm Growth	649.18%	344.78%	-101.05%	-114.27%	-129.64%	-150.81%	-11,883.28%	-816.52%	-298.59%	-53.93%
Invested Capital Growth	-577.78%	-18,707.00%	-18.22%	-9.02%	3.16%	36.34%	48.66%	54.36%	50.29%	64.15%
Revenue Q/Q Growth	0.00%	-39.69%	211.15%	31.16%	57.90%	95.42%	-59.41%	-19.06%	-43.05%	392.14%
EBITDA Q/Q Growth	9.67%	-24.19%	-1.01%	5.81%	12.07%	85.22%	-920.30%	-13.08%	-12.59%	42.11%
EBIT Q/Q Growth	9.16%	-24.52%	-1.47%	5.34%	11.39%	81.33%	-701.21%	-12.91%	-12.24%	40.83%
NOPAT Q/Q Growth	11.53%	-24.52%	-1.47%	5.34%	11.39%	81.33%	-701.21%	-12.91%	-12.24%	40.83%
Net Income Q/Q Growth	10.38%	-21.19%	-0.61%	5.17%	13.25%	88.07%	-1,185.16%	-12.31%	-14.15%	43.32%
EPS Q/Q Growth	10.34%	-19.23%	0.00%	6.45%	13.79%	108.00%	-1,650.00%	-12.90%	-8.57%	71.05%
Operating Cash Flow Q/Q Growth	13.09%	-21.40%	161.00%	-323.70%	6.61%	-31.83%	89.06%	-868.79%	5.26%	-27.09%
Free Cash Flow Firm Q/Q Growth	-1.62%	8.17%	-100.99%	-1,253.09%	-104.39%	-85.42%	-80.46%	-3.49%	11.11%	28.39%
Invested Capital Q/Q Growth	5.12%	4.62%	-35.10%	10.84%	15.71%	37.30%	-33.54%	20.74%	8.20%	54.78%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-398.40%	-820.37%	-266.33%	-191.26%	-106.50%	-8.05%	-202.46%	-282.88%	-559.27%	-65.78%
Operating Margin	-407.00%	-840.33%	-274.04%	-197.76%	-110.97%	-10.60%	-209.21%	-291.86%	-575.24%	-69.16%
EBIT Margin	-407.00%	-840.33%	-274.04%	-197.76%	-110.97%	-10.60%	-209.21%	-291.86%	-575.24%	-69.16%
Profit (Net Income) Margin	-400.30%	-804.34%	-260.10%	-188.04%	-103.31%	-6.30%	-199.60%	-276.97%	-555.20%	-63.94%
Tax Burden Percent	100.00%	100.45%	100.00%	100.00%	100.08%	99.30%	100.00%	100.00%	100.00%	101.61%
Interest Burden Percent	98.35%	95.29%	94.91%	95.09%	93.02%	59.90%	95.40%	94.90%	96.52%	90.98%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-105.40%	-134.49%	-187.82%	-272.38%	-428.87%	-129.63%	-197.34%	-392.69%	-102.63%	-48.16%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-13.35%	-46.90%	-25.55%	-35.93%	-34.24%	-4.90%	-109.76%	-188.04%	-205.40%	-13.44%
Return on Assets (ROA)	-13.13%	-44.89%	-24.25%	-34.17%	-31.87%	-2.92%	-104.71%	-178.44%	-198.25%	-12.42%
Return on Common Equity (ROCE)	-105.40%	-134.49%	-187.82%	-272.38%	-428.87%	-129.63%	-197.34%	-392.69%	-102.63%	-48.16%
Return on Equity Simple (ROE_SIMPLE)	-178.19%	0.00%	-466.78%	-1,070.13%	1,636.02%	0.00%	-131.89%	-242.96%	-49.97%	0.00%
Net Operating Profit after Tax (NOPAT)	-4.53	-5.65	-5.73	-5.42	-4.81	-0.90	-7.19	-8.11	-9.11	-5.39
NOPAT Margin	-284.90%	-588.23%	-191.83%	-138.43%	-77.68%	-7.42%	-146.45%	-204.31%	-402.67%	-48.41%
Net Nonoperating Expense Percent (NNEP)	-4.37%	-5.94%	-4.20%	-4.70%	-4.64%	0.35%	-6.61%	-9.50%	-6.46%	-1.81%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-3.97%	-	-	-	-3.70%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	161.16%	291.12%	117.52%	72.68%	48.84%	28.37%	82.98%	77.00%	153.15%	38.39%
R&D to Revenue	345.85%	649.21%	256.52%	225.08%	162.13%	82.23%	226.23%	314.87%	522.09%	130.77%
Operating Expenses to Revenue	507.00%	943.90%	374.04%	297.76%	211.06%	110.61%	309.21%	391.86%	675.24%	170.17%
Earnings before Interest and Taxes (EBIT)	-6.48	-8.07	-8.18	-7.75	-6.86	-1.28	-10	-12	-13	-7.70
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-6.34	-7.87	-7.95	-7.49	-6.59	-0.97	-9.93	-11	-13	-7.32
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	9.47	8.27	17.17	44.23	0.00	6.66	11.57	13.19	7.25	4.31
Price to Tangible Book Value (P/TBV)	9.47	8.27	17.17	44.23	0.00	6.66	11.57	13.19	7.25	4.31
Price to Revenue (P/Rev)	91.78	38.19	19.24	12.77	6.27	5.98	7.87	5.59	21.31	28.18
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	64.62	23.28	11.70	9.13	4.48	4.41	6.52	4.63	17.79	21.37
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	16.61	12.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	25.08	10.61	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.22	0.29	0.54	1.24	-1.89	0.00	0.18	0.29	0.05	0.00
Long-Term Debt to Equity	0.22	0.29	0.54	1.24	-1.89	0.00	0.18	0.29	0.05	0.00
Financial Leverage	-1.61	-1.62	-3.14	-3.85	-5.01	-2.26	-3.20	-4.27	-1.61	-1.14
Leverage Ratio	1.86	2.12	3.85	4.85	6.68	3.16	4.19	5.92	1.96	1.36
Compound Leverage Factor	1.83	2.02	3.65	4.61	6.21	1.90	4.00	5.62	1.89	1.24
Debt to Total Capital	17.96%	22.27%	35.23%	55.28%	212.53%	0.00%	15.48%	22.69%	4.71%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	17.96%	22.27%	35.23%	55.28%	212.53%	0.00%	15.48%	22.69%	4.71%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	82.04%	77.73%	64.77%	44.72%	-112.53%	100.00%	84.52%	77.31%	95.29%	100.00%
Debt to EBITDA	-0.12	-0.12	-0.11	-0.11	-0.11	0.00	-0.14	-0.12	-0.10	0.00
Net Debt to EBITDA	1.57	1.31	1.42	1.16	0.84	0.00	1.46	0.91	2.35	0.00
Long-Term Debt to EBITDA	-0.12	-0.12	-0.11	-0.11	-0.11	0.00	-0.14	-0.12	-0.10	0.00
Debt to NOPAT	-0.17	-0.16	-0.16	-0.16	-0.16	0.00	-0.18	-0.16	-0.13	0.00
Net Debt to NOPAT	2.21	1.83	1.99	1.61	1.16	0.00	2.00	1.24	3.23	0.00
Long-Term Debt to NOPAT	-0.17	-0.16	-0.16	-0.16	-0.16	0.00	-0.18	-0.16	-0.13	0.00
Altman Z-Score	-0.91	-2.32	-2.61	-3.21	-4.96	-0.54	-0.44	-3.22	9.76	14.39
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.05	1.82	1.25	1.11	0.90	1.63	1.57	1.37	4.19	7.77
Quick Ratio	2.01	1.76	1.22	1.08	0.87	1.26	1.51	1.32	4.15	7.21
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	19	21	-0.21	-2.78	-5.68	-11	-25	-25	-23	-16
Operating Cash Flow to CapEx	-1,019.61%	-994.47%	1,210.87%	-6,931.29%	-3,263.47%	-2,075.54%	-208.42%	-20,365.43%	-127,309.72%	-3,027.08%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.03	0.06	0.09	0.18	0.31	0.46	0.52	0.64	0.36	0.19
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.62	0.80	1.55	2.55	3.22	4.96	5.06	5.22	4.44	4.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-28	-27	-36	-32	-27	-17	-18	-15	-13	-6.05
Invested Capital Turnover	-0.10	-0.19	-0.17	-0.31	-0.51	-1.16	-1.00	-1.17	-1.15	-1.94
Increase / (Decrease) in Invested Capital	-24	-26	-5.52	-2.64	0.88	9.64	17	17	14	11
Enterprise Value (EV)	103	59	65	86	63	111	177	126	413	476
Market Capitalization	146	97	107	121	88	151	213	152	495	627
Book Value per Share	$0.63	$0.47	$0.25	$0.11	($0.07)	$0.73	$0.59	$0.36	$2.10	$3.20
Tangible Book Value per Share	$0.63	$0.47	$0.25	$0.11	($0.07)	$0.73	$0.59	$0.36	$2.10	$3.20
Total Capital	19	15	9.58	6.11	1.59	23	22	15	72	145
Total Debt	3.38	3.38	3.38	3.38	3.38	0.00	3.38	3.38	3.38	0.00
Total Long-Term Debt	3.38	3.38	3.38	3.38	3.38	0.00	3.38	3.38	3.38	0.00
Net Debt	-43	-38	-42	-34	-25	-39	-37	-26	-82	-152
Capital Expenditures (CapEx)	0.56	0.69	0.35	0.14	0.27	0.56	0.61	0.06	0.01	0.49
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-22	-22	-36	-34	-32	-20	-25	-21	-20	-9.16
Debt-free Net Working Capital (DFNWC)	24	19	9.46	3.77	-3.40	20	15	8.31	65	142
Net Working Capital (NWC)	24	19	9.46	3.77	-3.40	20	15	8.31	65	142
Net Nonoperating Expense (NNE)	1.84	2.07	2.04	1.94	1.59	-0.13	2.61	2.89	3.45	1.73
Net Nonoperating Obligations (NNO)	-43	-38	-42	-35	-25	-39	-37	-26	-82	-152
Total Depreciation and Amortization (D&A)	0.14	0.19	0.23	0.25	0.28	0.31	0.33	0.36	0.36	0.38
Debt-free, Cash-free Net Working Capital to Revenue	-1,401.34%	-866.92%	-644.79%	-359.81%	-227.19%	-79.05%	-91.85%	-77.89%	-84.73%	-41.12%
Debt-free Net Working Capital to Revenue	1,527.44%	756.51%	170.86%	39.88%	-24.19%	77.79%	55.46%	30.62%	281.33%	639.23%
Net Working Capital to Revenue	1,527.44%	756.51%	170.86%	39.88%	-24.19%	77.79%	55.46%	30.62%	281.33%	639.23%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.26)	($0.31)	($0.31)	($0.29)	($0.25)	$0.02	($0.31)	($0.35)	($0.38)	($0.11)
Adjusted Weighted Average Basic Shares Outstanding	24.43M	24.55M	25.25M	25.34M	25.82M	26.78M	31.35M	31.84M	33.09M	35.22M
Adjusted Diluted Earnings per Share	($0.26)	($0.31)	($0.31)	($0.29)	($0.25)	$0.02	($0.31)	($0.35)	($0.38)	($0.11)
Adjusted Weighted Average Diluted Shares Outstanding	24.43M	24.55M	25.25M	25.34M	25.82M	26.78M	31.35M	31.84M	33.09M	35.22M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	25.24M	25.26M	25.27M	25.78M	30.79M	31.40M	31.81M	32.54M	45.47M	45.68M
Normalized Net Operating Profit after Tax (NOPAT)	-4.53	-5.65	-5.73	-5.42	-4.80	-0.90	-7.19	-8.11	-9.11	-5.39
Normalized NOPAT Margin	-284.90%	-588.23%	-191.83%	-138.43%	-77.62%	-7.42%	-146.45%	-204.31%	-402.67%	-48.41%
Pre Tax Income Margin	-400.30%	-800.77%	-260.10%	-188.04%	-103.22%	-6.35%	-199.60%	-276.97%	-555.20%	-62.92%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Capricor Therapeutics' Financials

When does Capricor Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Capricor Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Capricor Therapeutics' net income changed over the last 2 years?

Capricor Therapeutics' net income appears to be on an upward trend, with a most recent value of -$40.47 million in 2024, rising from -$29.02 million in 2022. The previous period was -$22.29 million in 2023. See Capricor Therapeutics' forecast for analyst expectations on what’s next for the company.

What is Capricor Therapeutics's operating income?

Capricor Therapeutics's total operating income in 2024 was -$42.56 million, based on the following breakdown:

Total Gross Profit: $22.27 million
Total Operating Expenses: $64.95 million

How has Capricor Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Capricor Therapeutics' total revenue changed from $2.55 million in 2022 to $22.27 million in 2024, a change of 772.8%.

How much debt does Capricor Therapeutics have?

Capricor Therapeutics' total liabilities were at $25.02 million at the end of 2024, a 30.8% decrease from 2023, and a 34.7% decrease since 2022.

How much cash does Capricor Therapeutics have?

In the past 2 years, Capricor Therapeutics' cash and equivalents has ranged from $9.60 million in 2022 to $14.69 million in 2023, and is currently $11.29 million as of their latest financial filing in 2024.

How has Capricor Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Capricor Therapeutics' book value per share changed from 0.47 in 2022 to 3.20 in 2024, a change of 585.2%.

Related Companies

This page (NASDAQ:CAPR) was last updated on 5/6/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Capricor Therapeutics (CAPR) Financials

Frequently Asked Questions About Capricor Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Capricor Therapeutics (CAPR) Financials

Annual Income Statements for Capricor Therapeutics

Quarterly Income Statements for Capricor Therapeutics

Annual Cash Flow Statements for Capricor Therapeutics

Quarterly Cash Flow Statements for Capricor Therapeutics

Annual Balance Sheets for Capricor Therapeutics

Quarterly Balance Sheets for Capricor Therapeutics

Annual Metrics and Ratios for Capricor Therapeutics

Quarterly Metrics and Ratios for Capricor Therapeutics

Frequently Asked Questions About Capricor Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools